FindMyKOL
Clinical trialNCT06404112CompletedPhase 2Interventional

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)

NCT06404112 is a phase 2 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Melantonin Placebo and Melatonin in Long COVID, Long COVID-19 and 1 more condition. The registry lists an enrollment of 469 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2024 and a primary completion date of 26 Feb 2026.

SponsorDuke University →Enrollment469Long COVIDLong COVID-19Sleep Disturbance
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06404112
FieldValue
Registry IDNCT06404112
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorDuke University
Enrollment469
Registered sites1
Countries1
ConditionsLong COVID, Long COVID-19 and Sleep Disturbance
DrugsMelantonin Placebo and Melatonin
Start31 Jul 2024
Primary completion26 Feb 2026
Study completion1 Apr 2026
Last update posted8 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

North Carolina, United States1 site
  • All Sites Listed Under Nct06404086

    Durham

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Melantonin PlaceboMelatonin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06404112

Each answer restates registry values shown on this page.

What is NCT06404112?

NCT06404112 is a phase 2 interventional trial sponsored by Duke University. It studies Melantonin Placebo and Melatonin in Long COVID, Long COVID-19 and 1 more condition.

Who leads NCT06404112?

The registry names Christina Barkauskas, MD (study chair, Duke Clinical Research Institute) and Susan Redline, MD MPH (study chair, Brigham and Women's Hospital) as overall officials.

Where does NCT06404112 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06404112 study?

The registered drug and biological interventions are Melantonin Placebo and Melatonin.

When did NCT06404112 end?

The registry lists a primary completion date of 26 Feb 2026 and a study completion date of 1 Apr 2026. The sponsor last updated the record on 8 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.